RUSSIAN Original: ENGLISH

Женева, 20 ноября – 8 декабря 2006 года Пункт 10 повестки дня Рассмотрение действия Конвенции, как предусмотрено в ее статье XII

ПРЕДЛОЖЕНИЕ ПО МОДИФИКАЦИИ ФОРМАТА ФОРМ ПО МЕРАМ УКРЕПЛЕНИЯ ДОВЕРИЯ

Представлено Швейцарией

I. Цель настоящего рабочего документа

1. Меры укрепления доверия (МД) были введены на второй обзорной Конференции по КБО в 1986 году. На третьей обзорной Конференции по КБО в 1991 году формы по МД были и расширены, и пересмотрены. С тех пор никаких новых модификаций по содержанию или формату МД не производилось. Шестая обзорная Конференция по КБО в ходе своих заседаний произвела разбор мер укрепления доверия (МД), и было достигнуто широкое согласие на тот счет, что эта проблема заслуживает дальнейшего и всестороннего внимания. Швейцария также приняла к сведению заявления на шестой обзорной Конференции на тот счет, что некоторые государства-участники испытывают технические затруднения в связи с нынешними формами МД, и поэтому в настоящем рабочем документе она фокусируется конкретно на модификации форматов.

2. Швейцария считает, что более удобные в пользовании формы МД помогут увеличить число государств-участников, представляющих информацию на регулярной основе, а также повысить качество, точность и всеобъемлющий характер данных. Вдобавок Швейцария считает, что предлагаемые формы МД помогут свести к минимуму элементы двусмысленности.

3. Чтобы заложить основу для рассмотрений со стороны государств-участников в период до седьмой обзорной Конференции, Швейцария представляет полный набор форм МД. Предлагаемые формы пересмотрены с точки зрения формата с учетом также предложений со стороны других государств-участников в ходе данной Конференции. Хотя в формулировках имеют место кое-какие модификации, существо, согласованное третьей обзорной Конференцией, остается неизменным.

GE.07-60023 (R) 220107 220107

II. Предлагаемые формы МД

4. Формы МД, предлагаемые для рассмотрения государствами-участниками, фигурируют в прилагаемых приложениях (только на английском языке).

Приложение I	Форма 0 (объявление по форме "Объявлять нечего" или "Нет никаких новых изменений, подлежащих объявлению")
Приложение II	Формы 1-9 (охватывающие МД А-G).
Приложение III	Наставление для пользователя (приводит разъяснения, процедуры, определения справочного характера, как согласовано на третьей обзорной Конференции).

III. Предстоящий маршрут

5. Швейцария побуждает государства-участники рассмотреть предлагаемые формы и настоятельно призывает государства-участники включиться в плодотворный обмен взглядами и как можно скорее принять усовершенствованные формы.

6. Швейцария готова выслушать отзывы государств-участников на предмет дальнейшего усовершенствования форм МД и приглашает государства-участники представлять свои взгляды в период до седьмой обзорной Конференции.

Annex I

[English only]

CONVENTION ON THE PROHIBITION OF THE DEVELOPMENT, PRODUCTION AND STOCKPILING OF BACTERIOLOGICAL (BIOLOGICAL) AND TOXIN WEAPONS AND ON THEIR DESTRUCTION

CONFIDENCE-BUILDING MEASURES SUBMISSION FORMS

State Party to the Convention:

Date: _____

Form 0

Confidence Building Measures Nothing to declare or Nothing new to declare

0. A declaration on Nothing to declare or Nothing new to declare

This Form 0, in accordance with the agreement by States Party to the Convention at the Third Review Conference, contains all declarations on Nothing to declare or Nothing new to declare for the subsequent paragraphs 1 to 9.

In addition it guides through the declaration process and indicates what question needs to be addressed next.

Confidence-Building Measure A: Research centres, laboratories and national biological defence programmes:

- 1. Part 1: Research centres and laboratories;
- 2. Part 2: National biological defence research and development programmes.

Confidence-building measure B: Outbreaks of infectious diseases and similar occurrences caused by toxins:

- 3. Part 1: Background information on outbreaks of reportable infectious diseases;
- 4. Part 2: Outbreaks of infectious diseases and similar occurrences that seem to deviate from the normal pattern.
- 5. Confidence-building measure C: Encouragement of publication of results and promotion of use of knowledge.
- 6. Confidence-building measure D: Active promotion of contacts.
- 7. Confidence-building measure E: Legislation, regulations and other measures.
- 8. Confidence-building measure F: Past activities in offensive and/or defensive biological research and development programmes.
- 9. Confidence-building measure G: Vaccine production facilities.

Confidence Building Measures Nothing to declare or Nothing new to declare

CONFIDENCE-BUILDING MEASURE A

	Q1. Does your State Party have anything new to declare in		□ NO; it has nothing at all to declare on this form		urt 2, Question 3
relation to r	esearch centres	□ NO; informatio	on has already	Go to Question 2	
and laborate	ories?	been declared and	d has not changed		
		\Box YES; for the find	rst time	Go to Form 1	
		\Box YES; previousl	ly declared and	Go to Form 1	
		needs to update o	r modify details		
Q2. In which y	ear did your State P	arty provide this in	formation?		
□ 1987	□ 1988	□ 1989	□ 1990	□ 1991	□ 1992
□ 1993	□ 1994	□ 1995	1996	□ 1997	□ 1998
□ 1999	□ 2000	2001	□ 2002	□ 2003	□ 2004
□ 2005	□ 2006	2007	2008	□ 2009	□ 2010
□ 2011 (Go to CBM A Part 2, <i>Question 3</i>)				rt 2, Question 3)	

PART 1: RESEARCH CENTRES AND LABORATORIES

PART 2: NATIONAL BIOLOGICAL DEFENCE RESEARCH AND DEVELOPMENT PROGRAMMES

anything ne	anything new to declare in		□ NO; it has nothing at all to declare on this form		Go to CBM B Part 1, Question 5	
defence pro	national biological grammes?	□ NO; information has already been declared and has not changed		Go to Question 4		
		□ YES; previously declared and needs to update or modify details		Go to Form 2		
		□ YES; for the first time		Go to Form 2		
Q4. In which y	ear did your State F	Party provide this in	formation?	·		
□ 1987	□ 1988	□ 1989	□ 1990	□ 1991	□ 1992	
□ 1993	□ 1994	□ 1995	□ 1996	□ 1997	□ 1998	
□ 1999	□ 2000	2001	□ 2002	□ 2003	□ 2004	
□ 2005 □ 2006		□ 2007	□ 2008	□ 2009	□ 2010	
2011 (Go to CBM B Part 1, Question 5)						

Confidence Building Measures Nothing to declare or Nothing new to declare

CONFIDENCE-BUILDING MEASURE B

PART 1: BACKGROUND INFORMATION ON OUTBREAKS OF REPORTABLE INFECTIOUS DISEASES

anything ne	Q5. Does your State Party have anything new to declare in relation background		□ NO; it has nothing at all to declare on this form		Go to CBM B Part 2, <i>Question</i> 7	
	on outbreaks of	NO; information has already been declared and has not changed		Go to Question 6		
diseases?		□ YES; previously declared and needs to update or modify details		Go to Form 3		
		□ YES; for the first time		Go to Form 3		
Q6. In which y	ear did your State F	arty provide this in	formation?			
□ 1987	□ 1988	□ 1989	□ 1990	□ 1991	□ 1992	
□ 1993	□ 1994	□ 1995	□ 1996	□ 1997	□ 1998	
□ 1999	□ 2000	□ 2001	□ 2002	□ 2003	□ 2004	
□ 2005	□ 2006	□ 2007	□ 2008	□ 2009	□ 2010	
2011 (Go to CBM B Part 2, <i>Question</i> 7)						

PART 2: OUTBREAKS OF INFECTIOUS DISEASES AND SIMILAR OCCURRENCES THAT SEEM TO DEVIATE FROM THE NORMAL PATTERN

anything ne	Q7. Does your State Party have anything new to declare in relation to outbreaks of infectious diseases and similar occurrences that seem		□ NO; it has nothing at all to declare on this form		uestion 9	
infectious d			□ NO; information has already been declared and has not changed			
to deviate f pattern?	to deviate from the normal pattern?		□ YES; previously declared and needs to update or modify details		Go to Form 4	
		□ YES; for the first time		Go to Form 4		
Q8. In which y	ear did your State F	Party provide this in	formation?	·		
□ 1987	□ 1988	□ 1989	□ 1990	□ 1991	□ 1992	
□ 1993	□ 1994	□ 1995	□ 1996	□ 1997	□ 1998	
□ 1999	□ 2000	2001	□ 2002	□ 2003	2004	
□ 2005 □ 2006		2007	□ 2008	□ 2009	□ 2010	
□ 2011 (Go to CBM C, <i>Question 9</i>)				uestion 9)		

Confidence Building Measures Nothing to declare or Nothing new to declare

CONFIDENCE-BUILDING MEASURE C

ENCOURAGEMENT OF PUBLICATION OF RESULTS AND PROMOTION OF USE OF KNOWLEDGE

-	Q9. Does your State Party have anything new to declare in relation to the encouragements of publication of results and promotion of use of knowledge?		□ NO; it has nothing at all to declare on this form		Go to CBM D, Question 11	
			□ NO; information has already been declared and has not changed		Go to Question 10	
			□ YES; previously declared and needs to update or modify details		Go to Form 5	
			□ YES; for the first time		Go to Form 5	
Q10.	In which ye	ear did your State P	arty provide this in	formation?	I	
□ 19	87	□ 1988	□ 1989	□ 1990	□ 1991	□ 1992
□ 19	93	□ 1994	□ 1995	□ 1996	□ 1997	□ 1998
□ 19	99	□ 2000	□ 2001	□ 2002	□ 2003	□ 2004
20	005	2006	□ 2007	□ 2008	□ 2009	□ 2010
20	□ 2011 (Go to CBM D, <i>Question 11</i>)					uestion 11)

CONFIDENCE-BUILDING MEASURE D

ACTIVE PROMOTION OF CONTACTS

Q11. Does your State Party have anything new to declare in		□ NO; it has nothing at all to declare on this form		Go to CBM D, <i>Question 13</i>	
	relation to active promotion of contacts?		□ NO; information has already been declared and has not changed		2
		□ YES; previously declared and needs to update or modify details		Go to Form 6	
		□ YES; for the first time		Go to Form 6	
Q12. In which y	ear did your State F	arty provide this in	formation?		
□ 1987	□ 1988	□ 1989	□ 1990	□ 1991	□ 1992
□ 1993	□ 1994	□ 1995	□ 1996	□ 1997	□ 1998
□ 1999	□ 2000	2001	□ 2002	□ 2003	□ 2004
□ 2005	□ 2006	2007	□ 2008	□ 2009	□ 2010
□ 2011 (Go to CBM E, <i>Question 13</i>)				uestion 13)	

Confidence Building Measures Nothing to declare or Nothing new to declare

CONFIDENCE-BUILDING MEASURE E

LEGISLATION, REGULATIONS AND OTHER MEASURES

Q13. Does your State Party have anything new to declare in relation to legislation,		□ NO; it has nothing at all to declare on this form		Go to CBM F, Question 15	
regulations measures?		□ NO; information has already been declared and has not changed		Go to Question 14	
		□ YES; previously declared and needs to update or modify details		Go to Form 7	
		□ YES; for the first time		Go to Form 7	
Q14. In which y	ear did your State F	Party provide this in	formation?		
1987	□ 1988	□ 1989	□ 1990	□ 1991	□ 1992
□ 1993	□ 1994	□ 1995	□ 1996	□ 1997	□ 1998
□ 1999	□ 2000	2001	□ 2002	□ 2003	2004
2005	□ 2006	2007	□ 2008	□ 2009	□ 2010
□ 2011 (Go to CBM F, <i>Question 15</i>)				uestion 15)	

CONFIDENCE-BUILDING MEASURE F

PAST ACTIVITIES IN OFFENSIVE AND/OR DEFENSIVE BIOLOGICAL RESEARCH AND DEVELOPMENT PROGRAMMES

anything ne	Q15. Does your State Party have anything new to declare in relation to past activities in offensive and defensive biological research and development programmes?		□ NO; it has nothing at all to declare on this form		Go to CBM F, Question 17	
offensive an			□ NO; information has already been declared and has not changed		6	
developmer			□ YES; previously declared and needs to update or modify details		Go to Form 8	
		□ YES; for the first time		Go to Form 8		
Q16. In which y	ear did your State F	Party provide this in	formation?	1		
1987	□ 1988	□ 1989	□ 1990	□ 1991	□ 1992	
□ 1993	□ 1994	□ 1995	□ 1996	□ 1997	□ 1998	
□ 1999	□ 2000	□ 2001	□ 2002	□ 2003	□ 2004	
□ 2005	□ 2006	□ 2007	□ 2008	□ 2009	□ 2010	
2011				(Go to CBM G, Q	uestion 17)	

Confidence Building Measures Nothing to declare or Nothing new to declare

CONFIDENCE-BUILDING MEASURE G

VACCINE PRODUCTION FACILITIES

Q17. Does your State Party have anything new to declare in		□ NO; it has nothing at all to declare on this form		Go to Question 19)
relation to vaccine production facilities		□ NO; information has already been declared and has not changed		Go to Question 18	
		□ YES; previously declared and needs to update or modify details		Go to Form 9	
		□ YES; for the first time		Go to Form 9	
Q18. In which y	ear did your State P	Party provide this in	formation?	•	
□ 1987	□ 1988	□ 1989	□ 1990	□ 1991	□ 1992
□ 1993	□ 1994	□ 1995	□ 1996	□ 1997	□ 1998
□ 1999	□ 2000	2001	□ 2002	□ 2003	2004
□ 2005	□ 2006	□ 2007	□ 2008	□ 2009	□ 2010
$\Box 2011 \qquad (Go to Question 19)$					

Submission of CONFIDENCE-BUILDING MEASURE

Q19. Submit this Form 0 (filled in) and Forms 1 to 9, as applicable and in accordance with your national procedures, annually by **15** APRIL each year to

BWC Implementation Support Unit Department for Disarmament Affairs United Nations Office at Geneva Palais des Nations CH-1211 Geneva 10 Switzerland

Fax: +41 22 917 0483 E-mail: bwc@unog.ch

Annex II

[English only]

Form 1 Research centres and laboratories

CONFIDENCE-BUILDING MEASURE A

PART 1: RESEARCH CENTRES AND LABORATORIES

Complete a copy of Form A-P1-1 for each research centre or laboratory in your State Party which has any maximum containment laboratories meeting those criteria for such maximum containment laboratories as specified in the 1983 WHO Laboratory Biosafety Manual such as those designated as biosafety level 4 (BL4) or P4 or equivalent standards. Containment units which are fixed patient treatment modules, integrated with laboratories, should have a form of their own.

Q	1.1	Name of facility:		
Q	1.2	Is the facility being declared as part of	\Box NO; go to Q 1.3	3
		the national biological defence		
		programme in accordance with CBM A	\Box YES; go to For	rm 2, Section 3
		Part 2:	<i>,</i> 0	·
Q	1.3	Responsible public or private		
		organization or company:		
Q	1.4	Location and postal address:		
Q	1.5	Does the Ministry of Defence wholly		
`		or partially finance the reported	\Box YES \rightarrow Go to (Question 1.7
		activity?		-
			\Box NO \rightarrow Go to Q	Question 1.6
Q	1.6	What other governmental agencies or		
_		private entities wholly or partially		
		finance the facility?		
0	1.7	Number of maximum containment		1(m ²). 2 (m ²).
Q	1./	units in the facility (in accordance with		
		the WHO Laboratory Biosafety	2	3(m ²). 4 (m ²).
		Manual, 1983/2004, or equivalent)	3	5(m ²). 6 (m ²).
		and Indication of the size of the	\Box 4	7(m^2). 8(m^2).
		containment units:		9(m^2). 10(m^2).
				$11 _ (m^2). 12 _ (m^2).$
				13(m ²). 14(m ²).
			\Box If more than 7	15(m ²). 16 (m ²).
			How many:	17(m ²). 18 (m ²).
				19(m ²). 20 (m ²).
Q	1.9	If no maximum containment unit,		BSL 2
		indicate highest level of protection		_
		(equivalent to biosafety levels		BSL 3
		designated by WHO Laboratory		
		Biosafety Manual)		
Q	1.10	Scope and general description of		
		activities including type(s) of		
		microorganisms and/or toxins as		
		appropriate:		

Return to Form 0, CBM A part 2, Question 3

National biological defence research and development programmes

CONFIDENCE-BUILDING MEASURE A

PART 2: NATIONAL BIOLOGICAL DEFENCE RESEARCH AND DEVELOPMENT PROGRAMMES

Section I – Declaration

Q	2.1	Is there a national programme to	
		conduct biological defence research	\Box YES \rightarrow Go to Section II, Q 2.2
		and development within the territory	
		of the State Party, under its	\square NO \longrightarrow Go to CBM B (Form 3)
		jurisdiction or control anywhere?	
	diagn	1 0	e prophylaxis, studies on pathogenicity and virulence, , treatment, toxinology, physical protection,

Section II - Description

Q	2.2	State the objectives of the programme:
Q	2.3	Summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.
Q	2.4	Total funding for the programme and its source:

National biological defence research and development programmes

Q	2.5	Are aspects of this programme conducted under contract with industry, academic institutions, or in other non-defence facilities?	$\Box \text{ YES} \longrightarrow \text{Go to Question}$ $\Box \text{ NO} \longrightarrow \text{Go to Question 2}$	
Q	2.6	Proportion of the total funds of the programme expended on these contracted or other facilities? Summarize the objectives and researc	$\begin{array}{c c} \hline 1 - 10\% \\ \hline 21 - 30\% \\ \hline 41 - 50\% \\ \hline 61 - 70\% \\ \hline 81 - 90\% \\ \hline h \text{ areas of the programme perfet} \end{array}$	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$
	2.1	other facilities:	n aleas or the programme perio	
Q	2.8	Provide a diagram of the organisation (include individual facilities participat		and the reporting relationships
Q	2.9	How many facilities, both governmental and non- governmental, have a substantial proportion of their resources devoted to the national biological defence programme?	□ 1 □ 3 □ 5 □ 7 □ 9	□ 2 □ 4 □ 6 □ 8 □ 10 or more

Go to Section III

Form 2 National biological defence research and development programmes Section III - Facilities

Complete a copy of Form 2, Section III for each facility which has a substantial proportion of its resources devoted to the national biological defence programme and are within the territory of the reporting State, or under its jurisdiction or control anywhere. (Those listed in Q 2.9)

Q	2.10	Name of facility:	
Q	2.11	Location and postal address:	
Q	2.12	Total laboratory floor area:	m ²
Q	2.13	Floor area with containment level BSL 2 or equivalent:	m ²
Q	2.14	Floor area with containment level BSL 3 or equivalent:	m^2
Q	2.15	Floor area with containment level BSL 4 or equivalent:	m^2
Q	2.16	Total number of personnel:	
Q	2.17	Number of military personnel:	
Q	2.18	Number of civilian personnel:	
Q	2.19	Number of scientists:	
Q	2.20	Number of engineers	
Q	2.21	Number of technicians	
Q	2.22	Number of administrative staff:	
Q	2.23	List the scientific disciplines represented in the scientific / engineering staff.	
Q	2.24		$\begin{array}{l} \text{YES} \longrightarrow \text{Go to Question 2.25} \\ \text{NO} \longrightarrow \text{Go to Question 2.26} \end{array}$

Form 2			National biological defence research and development programmes
Q	2.25	Approximate number of contractor staff:	
Q	2.26	Does the Ministry of Defence wholly finance the facility?	\Box YES \longrightarrow Go to Question 2.28
			\square NO \longrightarrow Go to Question 2.27
Q	2.27	Other source(s) of financing:	
Q	2.28	Funding level for research	
Q	2.29	Funding level for development	
Q	2.30	Funding level for testing and evaluation:	
Q	2.31	Briefly describe the publication polic	
			Continue on additional pages if necessary
Q	2.32	12 months: (To include authors, title	
			Continue on additional page if necessary

Form 2	
	and development programmes
Form 2 Q 2.33	
	Continue on additional pages if necessary
<u> </u>	Return to Form 0, CBM B part 1, Question 5

Background information on outbreaks of reportable infectious diseases

CONFIDENCE-BUILDING MEASURE B

PART 1: BACKGROUND INFORMATION ON OUTBREAKS OF REPORTABLE INFECTIOUS DISEASES

Disease 10 years ago ago ago ago ago ago ago years ago ago years ago ago years ago ago year ago ago year				Number of c			
	Disease		5 years	4 years	3 years		
		ago	ago	ago	ago	ago	year
Continue on additional pages if necessary				Conti	nue on addit	ional pages i	f necessary

Return to Form 0, CBM B part 2, Question 7

Form 4

Outbreaks of infectious diseases and similar occurences that seem to deviate from the normal pattern

CONFIDENCE-BUILDING MEASURE B

PART 2: OUTBREAKS OF INFECTIOUS DISEASES AND SIMILAR OCCURRENCES THAT SEEM TO DEVIATE FROM THE NORMAL PATTERN

Complete a copy of Form 4 for each outbreak of infectious disease, or similar occurrence caused by toxins, that seems to deviate from the normal pattern. This form should be used, to the extent information is known and/or applicable, for the exchange of initial as well as annual information.

Q	4.1	Time of cognisance of outbreak:	
Q	4.2	Location of outbreak:	
Q	4.3	Approximate area affected:	
Q	4.4	Suspected source of disease or intoxication:	
			Continue on additional pages if necessary
Q	4.5	Possible causative agent(s):	
Q	4.6	Main characteristics of symptoms:	
			Continue on additional pages if necessary
Q	4.7	Approximate number of primary cases:	
Q	4.8	Approximate number of total cases:	
Q	4.9	Number of deaths:	
Q	4.10	Description of the development of the outbreak:	
			Continue on additional pages if necessary

Form 4 Outbreaks of infectious diseases and similar occurences that seem to deviate from the normal pattern

Q	4.11	Detailed respiratory symptoms:	
			Continue on additional pages if necessary
Q	4.12	Detailed neurological or behavioural	1.6
-		symptoms:	
			Continue on additional pages if necessary
Q	4.13	Detailed intestinal symptoms:	
		J 1	
			Continue on additional pages if necessary
Q	4.14	Detailed dermatological symptoms:	
×			
			Continue on additional pages if necessary
Q	4.15	Detailed nephrological symptoms:	
×	1.15	Detailed hepitological symptoms.	
			Continue on additional pages if necessary
Q	4.16	Detailed other symptoms:	- shalles on additional pages it necessary
V ا	4.10	Detaneti onici symptoms.	
			Continue on a dittional access if a second
			Continue on additional pages if necessary
Q	4.17	Deviation from the normal type of agent:	
			Continue on additional pages if necessary
L			

Form 4 Outbreaks of infectious diseases and similar occurences that seem to deviate from the normal pattern

Q	4.18	Deviation from the normal development of outbreak:	
			Continue on additional pages if necessary
Q	4.19	Deviation from the normal place of occurance of outbreak:	
			Continue on additional pages if necessary
Q	4.20	Deviation from the normal time of occurance of outbreak:	
	4.01		Continue on additional pages if necessary
Q	4.21	Deviation from the normal symptoms:	
			Continue on additional pages if necessary
Q	4.22	Deviation from the normal drug resistance pattern:	
			Continue on additional pages if necessary
Q	4.23	Deviation from the normal ability to diagnose the agent:	
			Continue on additional pages if necessary
Q	4.24	Deviation from the normal presence of vectors:	
			Continue on additional pages if necessary
Q	4.25	Other deviations:	
			Continue on additional pages if necessary

Form 4 Outbreaks of infectious diseases and similar occurences that seem to deviate from the normal pattern

Q 4.26 Measures taken:

Continue on additional pages if necessary

Return to Form 0, CBM C, Question 9

Encouragement of publication of results and promotion of use of knowledge

CONFIDENCE-BUILDING MEASURE C

Q	5.1	Briefly provide information on the general policy regarding publication of results of biological research:
		Continue on additional pages if necessary
Q	5.2	Briefly provide information on the policy regarding publication of results of biological research from research centres and laboratories relevant to CBM A.1:
		Continue on additional pages if necessary

Fo	orm 5	Encouragement of publication of results and promotion of use of knowledge
Q	5.3	Briefly provide information on the policy regarding publication of results of biological research from national biological defence programme facilities relevant to CBM A.2:
Q	5.4	Continue on additional pages if necessary Briefly provide information on the policy regarding publication of results of biological research on outbreaks of diseases covered by CBM B: Continue on additional pages if necessary
Q	5.5	Briefly provide information on relevant scientific journals and other relevant scientific publications generally available to States Parties: Continue on additional pages if necessary

Active promotion of contacts

CONFIDENCE-BUILDING MEASURE D

Section I – Planned international conferences, symposia, seminars, and other forums for exchange

Complete a copy of Form 6, Section I, for of the events listed above.

Q 6.1	Name of event:
Q 6.2	Arranging organization(s):
Q 6.3	Date(s):
Q 6.4	Location:
Q 6.5	Main subject(s) of the event:
Q 6.6	Conditions for participation:
Q 6.7	Point of contact for further information, registration, etc.:

Active promotion of contacts

Section II – Information regarding other opportunities

Q 6.8 Please provide details of other opportunities for the active promotion of contacts:

Continue on additional pages if necessary

Return to Form 0, CBM E, Question 13

Form 7

Legislation, regulations and other measures

Q 7.1	7.1 Indicate if the State Party has any of the following:					
	Measures Relating to:		Legislation	Regulations	Other Measures	Amended since last year
	The development, production, stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I:		YES	□ YES	YES	YES
	The export of microorganisms and toxins: The import of microorganisms and toxins:		YES	□ YES	YES	□YES
			YES	YES	YES	□YES
				□NO		
			If any of the above questions is answered with yes \rightarrow go to Question 7.2			
Q 7.2	Provide details of relevant measures:		1			
	Title	Date	Summary			
	Continue on additional pages if necessary					if necessary

CONFIDENCE-BUILDING MEASURE E

Return to Form 0, CBM F, Question 15

Past activities in offensive and/or defensive biological research and development programmes

Q	8.1	Date of entry into force of the	
Q	8.2	Convention for the State Party: Has the State Party had an offensive biological research and development programme?	□ YES \rightarrow Go to Question 8.3 □ NO \rightarrow Go to Question 8.5
Q	8.3	Provide the period(s) of related activities:	
Q	8.4		evelopment activities indicating whether work was tion, weaponization, stockpiling of biological agents, the d weapons, and other related research:
			Continue on additional pages if necessary
Q	8.5	Has the State Party had a defensive biological research and development programme?	Continue on additional pages if necessary ☐ YES → Go to Question 8.6 ☐ NO →Go to CBM G
Q Q	8.5	biological research and development	$\Box \text{ YES} \rightarrow \text{Go to Question 8.6}$
		biological research and development programme? Provide the period(s) of related activities: Provide a summary of the research and de conducted in the following areas: prophyl	YES → Go to Question 8.6 NO →Go to CBM G evelopment activities indicating whether work was laxis, studies on pathogenicity and virulence, diagnostic nent, toxinology, physical protection, decontamination,

CONFIDENCE-BUILDING MEASURE F

Return to Form 0, CBM G, Question 17

Vaccine production facilities

CONFIDENCE-BUILDING MEASURE G

Complete a copy of Form 6, Section I, for of each vaccine production facility.

Q	9.1	Name of facility:
Q	9.2	Location and postal address:
Q	9.3	General description of the types of diseases covered:
		Continue on additional pages if necessary Return to Form 0. Submission 0.19

Return to Form 0, Submission, Q 19

Annex III

[English only]

CONVENTION ON THE PROHIBITION OF THE DEVELOPMENT, PRODUCTION AND STOCKPILING OF BACTERIOLOGICAL (BIOLOGICAL) AND TOXIN WEAPONS AND ON THEIR DESTRUCTION

CONFIDENCE-BUILDING MEASURES

USER MANUAL FOR FILLING IN SUBMISSION FORMS

Introduction

1. This user manual is intended to provide the individual(s) tasked with the completion of the CBM Forms with the necessary information to do so in an efficient manner. The manual contains modalities, explanations, definitions and footnotes that are contained in the forms agreed to by the Third and Fourth Review Conferences, respectively.

2. The structure and logic of the revised CBM forms is as follows: Form 0 is the starting point of each annual reporting. Form 0 asks whether there is anything to be declared and, if so, on which of the forms 1 to 9 the information has to be filled in. Forms 1 to 9 then cover the substantive part of the CBM and upon completion will indicate where on Form 0 to continue.

Form 0:	A declaration on Nothing to declare or Nothing new to declare
Form 1:	Confidence-building Measure A: Research centres, laboratories and national biological defence programmes:
	Part 1: Research centres and laboratories.
Form 2:	Confidence-Building Measure A: Research centres, laboratories and national biological defence programmes:
	Part 2: National biological defence research and development programmes.
Form 3:	Confidence-building measure B: Outbreaks of infectious diseases and similar occurrences caused by toxins:
	Part 1: Background information on reportable infectious diseases.
Form 4:	Confidence-building measure B: Outbreaks of infectious diseases and similar occurrences caused by toxins:
	Part 2: Outbreaks of infectious disease and similar occurrences, that seem to deviate from the normal pattern.
Form 5:	Confidence-building measure C: Encouragement of publication of results and promotion of use of knowledge.
Form 6:	Confidence-building measure D: Active promotion of contacts.
Form 7:	Confidence-building measure E: Legislation, regulations and other measures.
Form 8:	Confidence-building measure F: Past activities in offensive and/or defensive biological research and development programmes.
Form 9:	Confidence-building measure G: Vaccine production facilities.

CONFIDENCE-BUILDING MEASURES

Form 0: Nothing to declare or Nothing new to declare

3. Form 0 asks for Confidence-Building Measures A to G whether the State Party has nothing at all or nothing new to declare.

4. If that is the case for any of the CBMs A to G, it is not necessary to go to the respective form but to continue with the subsequent questions on Form 0. If any question indicates that there is information to be submitted, Form 0 indicates on which of the Forms 1 to 9 the information is to be filled in. Upon completion of any of the Forms 1 to 9, these forms indicate where on Form 0 to continue with the process.

5. The set forms leads through the whole process in an easily understandable way and increase the internal consistency of the compiled set of forms.

6. Question 19 on Form 0 indicates to where the completed Form 0 and any of the Forms 1 to 9 (as applicable) are to be submitted.

CONFIDENCE-BUILDING MEASURE A

Form 1: Part 1: Research centres and laboratories

7. At the Third Review Conference it was agreed that States Parties continue to implement the following:

An exchange of data, including name, location, scope and general description of activities, on research centres and laboratories that meet very high national or international safety standards established for handling, for permitted purposes, biological materials that pose a high individual and community risk or specialize in permitted biological activities directly related to the Convention.

Modalities:

8. The Third Review Conference agreed data should be provided by States Parties on each facility, within their territory or under their jurisdiction or control anywhere, which has any maximum containment laboratories meeting those criteria for such maximum containment laboratories as specified in the 1983 WHO Laboratory Biosafety Manual such as those designated as biosafety level 4 (BL4) or P4 or equivalent standards.

Footnotes to Form 1:

- To the title of Part 1: The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
- To the name of Facility: Facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form 2 (CBM A, part 2 (iii))".
- To maximum containment units: In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.
 (currently valid version is the 2004 WHO Laboratory Biosafety Manual, ISBN 92 4 154650 6 (LC/NLM classification: QY 25) WHO/CDS/CSR/LYO/2004.11)

Form 2: Part 2: National biological defence research and development programmes

9. At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

States Parties will make declarations in accordance with the attached forms, which require the information in accordance with Form 2.

CONFIDENCE-BUILDING MEASURE B

Form 3: Part 1: Background information on outbreaks of reportable infectious diseasesForm 4: Part 2: Outbreaks of infectious diseases and similar occurrences that seem to deviate from the normal pattern

10. At the Third Review Conference it was agreed that States Parties continue to implement the following:

An exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins, and on all such events that seem to deviate from the normal pattern as regards type, development, place, or time of occurrence. The information provided on events that deviate from the norm will include, as soon as it is available, data on the type of disease, approximate area affected, and number of cases.

Modalities:

11. The Third Review Conference agreed the following definition:

An Outbreak or Epidemic is the occurrence of an unusually large or unexpected number of cases of an illness or health-related event in a given place at a given time. The number of cases considered as unusual will vary according to the illness or event and the community concerned.

Furthermore, reference was made to the following definition:

<u>An epidemic of infectious disease is defined as the occurrence of an unusually large or unexpected number of cases of a disease known or suspected to be of infectious origin, for a given place and time. It is usually a rapidly evolving situation, requiring a rapid response. (WHO internal document CDS/Mtg/82.1)</u>

The occurrence in a community or region of cases of an illness, specific health-related behaviour, or other health-related events clearly in excess of normal expectancy. The community or region, and the time period in which the cases occur, are specified precisely. The number of cases indicating the presence of an epidemic will vary according to the agent, size and type of population exposed, previous experience or lack of exposure to the disease, and time and place of occurrence: epidemicity is thus relative to usual frequency of the disease in the same area, among the specified population, at the same season of the year. A single case of a communicable disease long absent from a population or first invasion by a disease not previously recognized in that area requires immediate reporting and full field investigation: two cases of such a disease associated in time and place may be sufficient evidence to be considered an epidemic. (J.M. Last, <u>A Dictionary of Epidemiology</u>, Oxford University Press, New York, Oxford, Toronto, 1983.)

- 12. The Third Review Conference agreed on the following:
 - In determining what constitutes an outbreak States Parties are recommended to take guidance from the above;
 - Since no universal standards exist for what might constitute a deviation from the normal pattern, States Parties agreed to utilize fully existing national reporting systems on human diseases as well as animal and plant diseases, where possible, and systems within the WHO to provide annual update, using Form 3, of background information on diseases caused by organisms which meet the criteria for risk groups II, III and IV according to the classification in the 1983 WHO Laboratory Biosafety Manual, the occurrence of which, in their respective areas, does not necessarily constitute a deviation from normal patterns;
 - Exchange of data on outbreaks that seem to deviate from the normal pattern is considered particularly important in the following cases:

- When the cause of the outbreak cannot be readily determined or the causative agent is difficult to diagnose (It is understood that this may include organisms made pathogenic by molecular biology techniques, such as genetic engineering);
- When the disease may be caused by organisms which meet the criteria for risk groups III or IV, according to the classification in the 1983 WHO Laboratory Biosafety Manual;
- When the causative agent is exotic to a given region;
- When the disease follows an unusual pattern of development;
- When the disease occurs in the vicinity of research centres and laboratories subject to exchange of data under item A;
- When suspicions arise of the possible occurrence of a new disease.
- In order to enhance confidence, an initial report of an outbreak of an infectious disease or a similar occurrence that deviate from the normal pattern should be given promptly after cognizance of the outbreak and should be followed up by annual reports. To enable States Parties to follow a standardized procedure, the Conference has agreed that Form 4 should be used, to the extent information is known and/or applicable, for the exchange of initial as well as annual information.
- In order to improve international cooperation in the field of peaceful bacteriological (biological) activities and in order to prevent or reduce the occurrence of ambiguities, doubts and suspicions, States Parties are encouraged to invite experts from other States Parties to assist in the handling of an outbreak, and to respond favourably to such invitations.

Footnotes to Form 2:

- To Deviation from normal patterns: This information should be provided in accordance with Form 2 (CBM B, part 1)
- To Causative Agent: It is understood that this may include organisms made pathogenic by molecular biology technique, such as genetic engineering.

CONFIDENCE-BUILDING MEASURE C

Form 5: Encouragement of publication of results and promotion of use of knowledge

13. At the Third Review Conference it was agreed that States parties continue to implement the following:

Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research.

Modalities:

- 14. The Third Review Conference agreed on the following:
 - It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.
 - States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, *inter alia*, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.
 - The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

CONFIDENCE-BUILDING MEASURE D

Form 6: Active promotion of contacts

15. At the Third Review Conference it was agreed that States parties continue to implement the following:

Active promotion of contacts between scientists, other experts and facilities engaged in biological research directly related to the Convention, including exchanges and visits for joint research on a mutually agreed basis.

Modalities:

16. The Third Review Conference agreed on the following:

In order to actively promote professional contacts between scientists, joint research projects and other activities aimed at preventing or reducing the occurrence of ambiguities, doubts and suspicions and at improving international cooperation in the field of peaceful bacteriological (biological) activities, States parties are encouraged to provide information, to the extent possible:

- On planned international conferences, seminars, symposia and similar events dealing with biological research directly related to the Convention;
- On other opportunities for exchange of scientists, joint research or other measures to promote contacts between scientists engaged in biological research directly related to the Convention.

CONFIDENCE-BUILDING MEASURE E

Form 7: Legislation, regulations and other measures

17. At the Third Review Conference the States parties agreed to implement the following:

As an indication of the measures which they have taken to implement the Convention, States parties shall declare whether they have legislation, regulations or other measures:

- to prohibit the development, production, stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery, specified in Article I of the Convention, within their territory or anywhere under their jurisdiction or control;
- (b) in relation to the export or import of micro-organisms pathogenic to man, animals and plants or of toxins in accordance with the Convention;

States parties shall complete the attached form (Form E) and shall be prepared to submit copies of the legislation or regulations, or written details of other measures on request to the United Nations Department for Disarmament Affairs or to an individual State party. On an annual basis States parties shall indicate, also on the attached form, whether or not there has been any amendment to their legislation, regulations or other measures.

Footnote to Form 7:

• To Import and Export of micro-organisms: Micro-organisms pathogenic to man, animals and plants in accordance with the convention.

CONFIDENCE-BUILDING MEASURE F

Form 8: Past activities in offensive and/or defensive biological research and development programmes

18. At the Third Review Conference it was agreed that States Parties:

In the interest of increasing transparency and openness, shall declare whether or not they conducted any offensive and/or defensive biological research and development programmes since 1 January 1946.

CONFIDENCE-BUILDING MEASURE G

Form 9: Vaccine production facilities

19. At the Third Review Conference it was agreed that States Parties:

To further increase the transparency of biological research and development related to the Convention and to broaden scientific and technical knowledge as agreed in Article X, will declare all facilities, both governmental and non-governmental, within its territory or under its jurisdiction or control anywhere, producing vaccines licensed by the State party for the protection of humans.